Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Actionable genomic alterations in RCC

Kyrollis Attalla, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the findings of a study describing the prevalence and landscape of actionable genomic alterations in renal cell carcinoma (RCC). Leading altered genes included TSC1 mutation, PIK3CA mutation and MET amplification. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.